Identifying the Key to Stopping Colorectal Cancer Metastasis

A Spanish scientific team has identified the protein tropomodulin-2 (TMOD2) as a key element in the development of metastasis in patients with colorectal cancer, according to a study published in the prestigious British Journal of Cancer. The research, led by the Carlos III Health Institute (ISCIII) in collaboration with the San Carlos Clinical Hospital, the Jiménez Díaz Foundation, and the CIB-CSIC, demonstrates that this protein could become a promising therapeutic target for developing new treatments against this disease.

The results of the scientific work have confirmed that the expression of TMOD2 is altered in colorectal cancer tumor cells with a high capacity to generate liver metastases. "Our findings demonstrate that TMOD2 plays a relevant role in the progression of this type of cancer, which makes it a good candidate for developing new therapies in metastatic colorectal cancer that could, in the future, be tested in clinical trials," stated the scientific team, coordinated by Rodrigo Barderas and Ana Montero, from the Functional Research Unit on Chronic Diseases (UFIEC) at the ISCIII.

This discovery not only identifies a key mechanism in tumor progression, but it also establishes a direct correlation between elevated levels of this protein, advanced stages of the disease, and a significant reduction in the survival of the affected patients.

Advanced methodology to identify the metastatic mechanism

To reach these conclusions, the researchers used a multidisciplinary approach that combined proteomics techniques, bioinformatics, and analysis of tumor samples both in vitro and in vivo. This methodology allowed observing how the overexpression of TMOD2 in colorectal cancer cells causes a significant increase in their tumorigenic characteristics, increasing cell adhesion, tumor growth, and the ability to generate metastasis.

The experiments conducted demonstrated that cells with elevated levels of TMOD2 formed larger tumors compared to control groups. Additionally, it was observed that these cells had a greater capacity to colonize the liver, the main target organ for metastasis in this type of cancer.

"The research has allowed us to identify potential biomarkers that could be used to predict the risk of metastasis in patients with colorectal cancer, which would open the door to more personalized treatments," explain sources from the ISCIII consulted by this media.

The study also managed to identify other proteins and cellular pathways directly related to the overexpression of TMOD2 that participate in tumor and metastatic development. Among them, STAG1 and MARCKS, two proteins that seem to interact with TMOD2 in a complex molecular network that facilitates cancer progression.

These findings provide a deeper understanding of the molecular mechanisms underlying the metastatic process of colorectal cancer, especially in its spread to the liver, the organ most frequently affected by metastasis in this type of tumors.

"The knowledge gained about these signaling pathways could allow the development of therapeutic strategies targeted not only against TMOD2 but also against these associated proteins, potentially increasing the efficacy of treatments," the researchers note.

Implications for the diagnosis and prognosis of colorectal cancer

In addition to its potential as a therapeutic target, the identification of TMOD2 as a biomarker could significantly improve the diagnostic and prognostic tools currently available. Early detection of elevated levels of this protein in patients with colorectal cancer could help identify those at higher risk of developing metastasis.

"These results could translate into clinical tests that allow anticipating the behavior of the tumor and adapting treatments in a personalized way," explains the research team. "Patients with overexpression of TMOD2 could benefit from more intensive monitoring and more aggressive therapies aimed at preventing metastatic spread."

Colorectal cancer is one of the leading causes of cancer mortality in Spain, with more than 40,000 new cases diagnosed annually. The identification of new biomarkers like TMOD2 represents a significant advancement in the fight against this disease.

Tropomodulin-2: a key protein in tumor metastasis

Tropomodulin-2 (TMOD2) is a protein that belongs to the family of proteins that regulate the cellular cytoskeleton. Traditionally, it had been studied mainly in neuronal tissue, where it plays important roles in the stabilization of actin filaments, essential components of the cellular cytoskeleton.

However, this new study reveals its unexpected role in the progression of colorectal cancer, where it appears to facilitate cell mobility, tissue invasion, and the ability of tumor cells to survive in environments different from their origin. These characteristics are fundamental for the development of the metastatic process.

What treatments could be developed from this discovery?

The finding of TMOD2 as a key protein in the development of metastasis of colorectal cancer opens various therapeutic possibilities that could be explored in the coming years. Among the most promising strategies are:

1. Specific inhibitors of TMOD2 that block its activity in tumor cells.
2. Targeted therapies that interfere with the interaction between TMOD2 and other proteins such as STAG1 and MARCKS.
3. Immunotherapies based on monoclonal antibodies against TMOD2.
4. Gene therapies that reduce the expression of TMOD2 in tumor cells.

Although these therapeutic approaches are still in experimental phase and will require years of additional research before reaching clinical practice, they represent a significant hope for improving the prognosis of patients with metastatic colorectal cancer, a condition that currently has limited treatment options and generally unfavorable prognosis.